Drugs / GSK2636771
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02215096 | Nov 2014 → Oct 2019 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01458067 | Nov 2011 → Nov 2015 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03131908 | Jul 2017 → Dec 2027 expected | metastatic melanoma, skin cancer | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02615730 | Feb 2016 → Mar 2021 | gastric adenocarcinoma | Yonsei University | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04439149 | May 2016 → Nov 2020 overdue | adult lymphoma, plasma cell myeloma, refractory hematologic cancer, refractory malignant neoplasm | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04439188 | Mar 2016 → Nov 2020 overdue | adult lymphoma, plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02465060 | Aug 2015 → Dec 2027 expected | breast carcinoma, carcinoma of esophagus, cervical carcinoma, colon carcinoma +17 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2636771 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01458067 ↗ |
| Action | Inhibit | “PI3Kβ inhibitor GSK2636771” PMID 34281912 ↗ Oct 2021 |
| Modality | Small molecule | — CHEMBL3188551 ↗ |
| Route | Oral | “Oral capsules” NCT01458067 ↗ |
| Target | PIK3CB | “PIK3CB inhibitor GSK2636771” PMID 40865033 ↗ Aug 2025 |